Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Innate Pharma
CONTACT
Lead
Innate Pharma
Currently enrolling in Cohort 2: this is an open-label, single-arm multicenter study. Eligible NSCLC patients PD-L1 ≥1% will be enrolled and will receive IPH5201 + Durvalumab + standard of care chemotherapy before surgery.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted